Neoplasms, Cystic, Mucinous, and Serous clinical trials
The registry lists 21 studies for Neoplasms, Cystic, Mucinous, and Serous across more than 10 countries. 4 are recruiting or about to start. 14 of them are mainly about Neoplasms, Cystic, Mucinous, and Serous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 5 narrower conditions too, such as Pseudomyxoma Peritonei: 97 studies, 28 open.
Get an email when these change. Save the Neoplasms, Cystic, Mucinous, and Serous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Royal Marsden NHS Foundation Trust (3) · Mayo Clinic (2) · Mucpharm Pty Ltd (1) · West China Hospital (1) · Massachusetts General Hospital (1) · Boston Scientific Corporation (1) · Ohio State University Comprehensive Cancer Center (1) · Indiana University (1)
What is being tested here
Drugs under test in Neoplasms, Cystic, Mucinous, and Serous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Irinotecan sucrosofate | 0 | 0 | 1 |
| Irinotecan | 0 | 0 | 1 |
| Ethanol | 0 | 0 | 1 |
| Bromelains | 0 | 0 | 1 |
| Acetylcysteine | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
Who these studies take
Of the 3 Neoplasms, Cystic, Mucinous, and Serous studies recruiting now, 2 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (33%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 21 studies, recruiting or not: 10% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic NeoplasmsRecruitingNCT07529483Phase 21 country
- Intent of Surgery for IPMNRecruitingNCT072165215 countries
- Inverted-Ω Anastomosis in Laparoscopic Duodenum-Preserving Pancreatic Head Resection or Laparoscopic Central PancreatectomyNot yet recruitingNCT07087392Not applicable1 country
- Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the PancreasRecruitingNCT054339351 country
- Intra-operative Pancreatoscopy in Patients With IPMNActive, not recruitingNCT037294536 countries
- Phase I Trial HIPEC With Nal-irinotecanCompletedNCT04088786Phase 11 country
- BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma PeritoneiStatus unknownNCT03976973Phase 2
- SpyGlass in Preoperative Diagnostics of Presumed Main Duct IPMNs: Efficacy and Novel Insights on ComplicationsCompletedNCT030621242 countries
- 18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot StudyCompletedNCT03352037Not applicable1 country
- Reliability of the Preoperative Work-up in Patients Submitted to Surgery for Cystic Neoplasms of the PancreasStatus unknownNCT026757381 country
- Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic TumorsWithdrawnNCT02882503Not applicable1 country
- Low Rectal Cancer Study (MERCURY II)Status unknownNCT020059653 countries
- Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksStatus unknownNCT01037049Phase 24 countries
- Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) TrialStatus unknownNCT019959421 country
- Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic TumorCompletedNCT02330497Not applicable1 country
- Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic NeoplasmsCompletedNCT02158039Phase 11 country
- Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the PancreasStatus unknownNCT00689715Phase 2/31 country
- Positron Emission Tomography-computed Tomography (PET-CT) for Main & Branch Intraductal Papillary Mucinous NeoplasmCompletedNCT009884161 country
- Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort StudyStatus unknownNCT02213419Phase 11 country
- Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic NeoplasmsWithdrawnNCT01057355Phase 1
- Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the PancreasTerminatedNCT00621556Phase 11 country